Globeflex Capital L P Invests $7.12 Million in Taro Pharmaceutical Industries Ltd. (NYSE:TARO) Stock

Globeflex Capital L P acquired a new stake in Taro Pharmaceutical Industries Ltd. (NYSE:TARO) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 72,459 shares of the company’s stock, valued at approximately $7,123,000. Taro Pharmaceutical Industries makes up approximately 1.4% of Globeflex Capital L P’s investment portfolio, making the stock its 3rd largest position. Globeflex Capital L P owned approximately 0.18% of Taro Pharmaceutical Industries as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in TARO. Moody National Bank Trust Division bought a new stake in Taro Pharmaceutical Industries during the 3rd quarter valued at $204,000. Engineers Gate Manager LP bought a new stake in Taro Pharmaceutical Industries during the 3rd quarter valued at $217,000. Hikari Power Ltd bought a new stake in Taro Pharmaceutical Industries during the 2nd quarter valued at $296,000. Ramsey Quantitative Systems bought a new stake in Taro Pharmaceutical Industries during the 2nd quarter valued at $360,000. Finally, Dynamic Technology Lab Private Ltd raised its holdings in Taro Pharmaceutical Industries by 31.1% during the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 3,230 shares of the company’s stock valued at $374,000 after buying an additional 766 shares during the last quarter. 10.46% of the stock is owned by institutional investors.

Shares of NYSE TARO opened at $106.01 on Thursday. Taro Pharmaceutical Industries Ltd. has a 12 month low of $93.01 and a 12 month high of $121.23. The firm has a market capitalization of $4.25 billion, a price-to-earnings ratio of 17.15 and a beta of 0.29.

Taro Pharmaceutical Industries (NYSE:TARO) last issued its quarterly earnings data on Monday, November 5th. The company reported $1.60 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.96 by ($0.36). Taro Pharmaceutical Industries had a return on equity of 11.99% and a net margin of 36.33%. The company had revenue of $158.97 million during the quarter, compared to the consensus estimate of $167.40 million. On average, sell-side analysts predict that Taro Pharmaceutical Industries Ltd. will post 7.65 earnings per share for the current fiscal year.

The business also recently disclosed a dividend, which will be paid on Friday, December 28th. Shareholders of record on Tuesday, December 11th will be issued a $12.81 dividend. The ex-dividend date is Monday, December 10th.

A number of equities research analysts recently commented on the stock. Zacks Investment Research lowered shares of Taro Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a report on Thursday, August 16th. HC Wainwright reiterated a “buy” rating and set a $120.00 price target on shares of Taro Pharmaceutical Industries in a report on Friday, August 10th. Finally, ValuEngine lowered shares of Taro Pharmaceutical Industries from a “hold” rating to a “sell” rating in a report on Monday, September 24th.

TRADEMARK VIOLATION WARNING: This story was published by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at https://www.baseballdailydigest.com/news/2018/12/06/72459-shares-in-taro-pharmaceutical-industries-ltd-taro-purchased-by-globeflex-capital-l-p.html.

Taro Pharmaceutical Industries Company Profile

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories.

See Also: What is the balance sheet?

Institutional Ownership by Quarter for Taro Pharmaceutical Industries (NYSE:TARO)

Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply